SOM Biotech secures €7m for repurposing drugs for rare CNS diseases
Spanish pharmaceutical company SOM Biotech has raised €7 million in a new financing round to support its work…
Here’s why the body may reject lung transplants
New Delhi, Mar 05 (ANI): A study led by researchers at Washington University School of Medicine in St.…
Aldevron expands antibody development facility in Freiburg, Germany
Aldevron, a US-based contract development and manufacturing organisation (CDMO), has unveiled plans to expand its antibody development facility…
Novartis secures FDA approval for Egaten as fascioliasis treatment
Novartis has achieved a significant milestone with the FDA’s approval of Egaten (triclabendazole) for the treatment of fascioliasis…
Clinigen to acquire US rights to Proleukin for up to $210m
British pharmaceutical company Clinigen has struck a deal with Swiss rival Novartis to acquire the US rights to…
Bexion Pharmaceuticals advances BXQ-350 cancer drug trial with phase 1 part 3 launch
Bexion Pharmaceuticals has launched part 3 of its phase 1 clinical trial for BXQ-350, an investigational cancer treatment…
Alexion Pharmaceuticals secures FDA priority review for SOLIRIS in neuromyelitis optica spectrum disorder
Alexion Pharmaceuticals has secured a significant milestone with the FDA granting priority review for its C5 complement inhibitor,…
Biohaven secures orphan drug status for verdiperstat in MSA treatment
Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for…
Chinese pharma giants Innovent Biologics and Shenzhen Chipscreen Biosciences join forces for advanced colorectal cancer drug trial
Innovent Biologics and Shenzhen Chipscreen Biosciences have entered into a major collaboration to assess the potential of a…
Swiss pharma Orphan Technologies launches phase 1/2 clinical trial for OT-58 in classical homocystinuria
Orphan Technologies, a Swiss pharmaceutical company, has officially dosed the first patients in its groundbreaking phase 1/2 clinical…